Based in Eden Prairie, Minn., NeoChord is a privately held medical technology company focused on advancing the treatment of mitral regurgitation. The Company received CE marking in December 2012 for the DS1000 device for minimally invasive mitral valve repair via surgical implantation of artificial chordae tendinae. Mitral regurgitation is a progressive disease that left untreated, can result in atrial fibrillation, congestive heart failure, and death.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/09/15 | $20,000,000 | Series C |
Baird Capital Deerfield Management Company, L.P. Heron Capital TGAP Ventures | undisclosed |
